2552 — Hua Medicine Income Statement
0.000.00%
Last trade - 00:00
- HK$1.30bn
- -HK$85.14m
- CNY76.61m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 17.6 | 76.6 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 7.69 | 37.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 424 | 389 | 322 | 217 | 280 |
Operating Profit | -424 | -389 | -322 | -200 | -203 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -425 | -393 | -326 | -204 | -211 |
Provision for Income Taxes | |||||
Net Income After Taxes | -425 | -393 | -326 | -204 | -211 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -425 | -393 | -326 | -204 | -211 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -425 | -393 | -326 | -204 | -211 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.451 | -0.417 | -0.341 | -0.21 | -0.216 |